Literature DB >> 16488991

Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner.

Lina I Yoo1, David W Liu, Sandrine Le Vu, Roderick T Bronson, Hong Wu, Junying Yuan.   

Abstract

PTEN deficiency predisposes to a subset of human cancers, but the mechanism that underlies such selectivity is unknown. We have generated a mouse line that conditionally deletes Pten in urogenital epithelium. These mice develop carcinomas at high frequency in the prostate but at relatively low frequency in the bladder, despite early and complete penetrance of hyperplasia in both organs. Cell proliferation is initially high in the bladder of newborn Pten-deficient mice but within days is inhibited by p21 induction. In contrast, proliferation remains elevated in Pten-deficient prostate, where p21 is never induced, suggesting that p21 induction is a bladder-specific compensatory mechanism to inhibit proliferation caused by Pten deletion. Furthermore, the AKT/mammalian target of rapamycin growth pathway, which is highly activated in Pten-deficient prostate, is not activated in bladder epithelium. Our results reveal alternative downstream signaling pathways activated by Pten deficiency that lead to tissue-specific susceptibilities to tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16488991     DOI: 10.1158/0008-5472.CAN-05-1986

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).

Authors:  Katarzyna Marcinkiewicz; Kymora B Scotland; Stephen A Boorjian; Emeli M Nilsson; Jenny Liao Persson; Per Anders Abrahamsson; Cinzia Allegrucci; Ieuan A Hughes; Lorraine J Gudas; Nigel P Mongan
Journal:  Int J Oncol       Date:  2011-09-28       Impact factor: 5.650

2.  A PTEN translational isoform has PTEN-like activity.

Authors:  Xie Zhang; Bowei Yin; Fangfang Zhu; Guochang Huang; Hong Li
Journal:  Chin J Cancer Res       Date:  2015-10       Impact factor: 5.087

3.  The role of WNT signalling in urothelial cell carcinoma.

Authors:  I Ahmad
Journal:  Ann R Coll Surg Engl       Date:  2015-08-14       Impact factor: 1.891

4.  Overexpression of DJ-1 and HSP90α, and loss of PTEN associated with invasive urothelial carcinoma of urinary bladder: Possible prognostic markers.

Authors:  Hojung Lee; Seung Kyu Choi; Jae Y Ro
Journal:  Oncol Lett       Date:  2011-12-13       Impact factor: 2.967

5.  PTEN gene silencing prevents HIV-1 gp120(IIIB)-induced degeneration of striatal neurons.

Authors:  Shiping Zou; Nazira El-Hage; Elizabeth M Podhaizer; Pamela E Knapp; Kurt F Hauser
Journal:  J Neurovirol       Date:  2011-01-14       Impact factor: 2.643

6.  Immunohistochemical expression of components of the Akt-mTORC1 pathway is associated with hepatocellular carcinoma in patients with chronic liver disease.

Authors:  Scott J Cotler; Nissim Hay; Hui Xie; Mei Ling Chen; Pei Zhang Xu; Thomas J Layden; Grace Guzman
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

7.  Pten haploinsufficiency accelerates formation of high-grade astrocytomas.

Authors:  Chang-Hyuk Kwon; Dawen Zhao; Jian Chen; Sheila Alcantara; Yanjiao Li; Dennis K Burns; Ralph P Mason; Eva Y-H P Lee; Hong Wu; Luis F Parada
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  Antigen-induced Pten gene deletion in T cells exacerbates neuropathology in experimental autoimmune encephalomyelitis.

Authors:  Trina A Johnson; Shigeki Tsutsui; Frank R Jirik
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

Review 9.  Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.

Authors:  Margaret A Knowles; Fiona M Platt; Rebecca L Ross; Carolyn D Hurst
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

Review 10.  Biology of urothelial tumorigenesis: insights from genetically engineered mice.

Authors:  Xue-Ru Wu
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.